JNJ

237.04

-1.23%↓

UNH

279.53

+1.13%↑

TMO

544.31

+0.42%↑

ABT

110.73

-0.08%↓

ISRG

491.79

+0.93%↑

JNJ

237.04

-1.23%↓

UNH

279.53

+1.13%↑

TMO

544.31

+0.42%↑

ABT

110.73

-0.08%↓

ISRG

491.79

+0.93%↑

JNJ

237.04

-1.23%↓

UNH

279.53

+1.13%↑

TMO

544.31

+0.42%↑

ABT

110.73

-0.08%↓

ISRG

491.79

+0.93%↑

JNJ

237.04

-1.23%↓

UNH

279.53

+1.13%↑

TMO

544.31

+0.42%↑

ABT

110.73

-0.08%↓

ISRG

491.79

+0.93%↑

JNJ

237.04

-1.23%↓

UNH

279.53

+1.13%↑

TMO

544.31

+0.42%↑

ABT

110.73

-0.08%↓

ISRG

491.79

+0.93%↑

Search

Simulations Plus Inc

Abierto

SectorSanidad

14.08 -3.23

Resumen

Variación precio

24h

Actual

Mínimo

13.42

Máximo

14.35

Métricas clave

By Trading Economics

Ingresos

1.4M

676K

Ventas

961K

18M

P/B

Media del Sector

48.528

84.243

BPA

-0.034

Rentabilidad por dividendo

0.48

Margen de beneficios

3.67

Empleados

212

EBITDA

-3M

2.3M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+30.4% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.28%

Próximas Ganancias

2 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-30M

338M

Apertura anterior

17.31

Cierre anterior

14.08

Noticias sobre sentimiento de mercado

By Acuity

68%

32%

310 / 352 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 feb 2026, 23:57 UTC

Charlas de Mercado

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8 feb 2026, 23:47 UTC

Charlas de Mercado

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8 feb 2026, 23:43 UTC

Charlas de Mercado

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8 feb 2026, 23:34 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 feb 2026, 23:34 UTC

Charlas de Mercado

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8 feb 2026, 23:26 UTC

Charlas de Mercado

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8 feb 2026, 22:55 UTC

Ganancias

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8 feb 2026, 22:55 UTC

Ganancias

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8 feb 2026, 22:55 UTC

Ganancias

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8 feb 2026, 22:55 UTC

Ganancias

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8 feb 2026, 22:55 UTC

Ganancias

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8 feb 2026, 22:55 UTC

Ganancias

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8 feb 2026, 21:43 UTC

Charlas de Mercado

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8 feb 2026, 21:16 UTC

Charlas de Mercado

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8 feb 2026, 21:15 UTC

Charlas de Mercado

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7 feb 2026, 09:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

7 feb 2026, 09:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

7 feb 2026, 05:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

7 feb 2026, 02:46 UTC

Adquisiciones, fusiones, absorciones

Big Money, High Anxiety -- Barrons.com

6 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 feb 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

6 feb 2026, 21:40 UTC

Adquisiciones, fusiones, absorciones

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 feb 2026, 21:22 UTC

Charlas de Mercado

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 feb 2026, 21:17 UTC

Ganancias

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 feb 2026, 21:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

6 feb 2026, 21:14 UTC

Adquisiciones, fusiones, absorciones

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 feb 2026, 21:13 UTC

Ganancias

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 feb 2026, 21:13 UTC

Ganancias

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 feb 2026, 21:04 UTC

Charlas de Mercado

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 feb 2026, 20:34 UTC

Ganancias

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

30.4% repunte

Estimación a 12 Meses

Media 19 USD  30.4%

Máximo 19 USD

Mínimo 19 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

310 / 352 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat